Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Transient Protein Expression Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 May 13
SKU : 3493
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Global Transient Protein Expression Market is segmented By Product Type (Instruments), By Application (Genomic Research, Gene Therapy, BioProduction, Cancer Research, Drug Development), By End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Clinical Research Organizations), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The global transient protein expression market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).  

 Transient protein expression is a procedure that is usually used to obtain a few milligrams of protein to a hundred milligrams of protein. It is a procedure expressed quickly once the DNA encoding expression has been introduced to animal or plant cells. It is performed using an electroporation technique that allows large numbers of mutants to be screened for their abilities to network productively with receptors and effectors. 


Market Dynamics

The transient protein expression market growth is driven by the increasing due to its rapid expression time and relatively low-cost product when compared to stable transfection. Additionally, rapidly developing biopharmaceuticals and technological advancements will also drive the growth of the global transient protein expression market.

Growing adoption of precision medicines, is expected to propel the global transient protein expression market growth over the forecast period

Technological advancements have increased the adoption of molecular biology techniques for developing various therapeutic or treatment modalities. Different therapeutic modalities utilize genomic, transcriptomic information that facilitates discovering biomarkers to monitor diseases and predicts their risks. The use of personalized or precision medicines has dramatically risen due to the awareness regarding genetic variations among people. For instance, mRNA-mediated therapy is used for treating several diseases, as the therapy is characterized by decreased immunogenicity, superior translation efficacy, enhanced stability, pharmaceutical safety, and transient protein expression, since only the mRNA is modified without incorporating the host genome.

Similarly, the pharmaceutical and biotechnology industries have developed various techniques to treat cancer and neurodegenerative diseases. The transient gene expression technique has led to significant developments in the research related to neurotrauma and neurodegenerative and resulted in the introduction of precision medicines for these conditions. Technological advancements in epigenetics, genetics and proteomics support the development of therapeutics to treat various genetic and rare genetic diseases caused by single and multiple cell disorders.

The Precision Medicine Initiative launched in the US in 2015 has enhanced the use of genetic engineering, genomics, and proteomics, thereby increasing the use of transient protein expression techniques. Thus, the continuous research and development activities and rise in government initiatives to support precision medicine boost the adoption of transient protein expression techniques.

Lack of requirements of skilled researcher is likely to hamper the market growth

Transient transfections are a fast, cost-effective solution but require skilled cell culture scientists, making the workforce a limiting factor in a setting where numerous samples are processed in parallel may restrict the market growth.

COVID-19 Impact Analysis

The COVID–19 pandemic has resulted in a rise in the use of transient protein expression in vaccine development. Various researchers have started studying the novel coronavirus extensively, with the use of transient protein expression. For instance, in March–April 2020, Absolute Antibody (UK) increased the production of multigram quantities of multiple anti-SARS-CoV-2 spike proteins to develop neutralizing antibodies. Similarly, the transient protein expression was widely used to produce a positive control protein in developing in-vitro diagnostics kits.

Segment Analysis

The instruments segment is expected to hold largest share in this market segment

The instruments segment held the largest market share. This segment is also expected to dominate the market as they reduce human input, enabling continuous cell maintenance and protein production. Moreover, the same segment is anticipated to grow at the fastest rate during the forecast period. For instance, the CompacT SelecT cell culture robot is designed to allow the large-scale expression of multiple protein constructs in a transient format.

The genomic research segment is expected to hold largest share in this market segment

This segment is also expected to dominate the market as it increases DNA sequencing performance. Moreover, transient protein expression has helped in studying all the genes of a person (the genome), including their interactions with each other and the environment.

The pharmaceutical and biotechnology companies’ segment is expected to hold largest share in this market segment

This segment is also expected to dominate the market during the forecast period as pharmaceutical and biotechnology firms increase their spending on research and R&D activities. Moreover, transient protein expression has helped the recent improvements in existing technologies, and it is moving toward the industrial production of plant-based vaccines, antibodies, and biopharmaceuticals. For instance, Jan 2020: Ambrx and Sino Biopharma Announced Collaboration to Develop Two Next-Generation Biologics to develop two products enabled by Ambrx's unique non-natural amino acid incorporation technology platforms. The collaboration combines Ambrx's clinically validated ReCODE and EuCODE platforms with Sino Biopharma's strong resources and commitment to bring next-generation biologic drugs to the market.


Geographical Analysis

North America region holds the largest market share of global transient protein expression market

North America dominated the transient protein expression market due to established research infrastructure and rising interest in research activities. Both U.S and Canada have shown high growth in the transient protein expression market due to well-established infrastructure and government-supported funding policies. Europe holds the second position due to the rising adoption of technology in academic research centers and both research laboratories. In terms of growth, Asia Pacific is anticipated to be the fastest-growing transient protein expression market over the forecast period due to increasing academic research and government policies and funding for research and development in these regions.

Competitive Landscape

The global transient protein expression market is highly competitive with presence of global companies.  Some of the key players which are contributing to the growth of the market include Thermo Fisher Scientific, Promega Corporation, Merck KGaA, Takara Bio Inc, Qiagen, Sigma-Aldrich, Bio-Rad Laboratories, Inc., Sino Biological Inc, Genscript Biotech Corporation, and Agilent Technologies Inc, Sino Biopharma. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in 2017, Thermo Fisher Scientific Inc. launched its new PureLink Fast Low-Endotoxin Plasmid Purification Midi and Maxi Kits, which significantly reduce plasmid purification time to accelerate protein expression.

Transient Protein Expression Market Key Companies to Watch

Agilent Technologies Inc

Company Overview: Agilent is a leader in life sciences, diagnostics and applied chemical markets established on Nov. 18, 1999. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. With the team of 16,300 employees spread across the world. The majority of research is located in the United States in Santa Clara, California, with additional locations in Europe and Asia.

Product Portfolio: The Company's products include Environmental and Forensics, Food, Pharmaceutical, Diagnostics, Research, Chemical and Energy.

Key Developments: In 2018 Agilent announced to sign a definitive agreement to acquire related businesses with young in Scientific Co. Ltd., a leading distributor of analytical and scientific instruments in South Korea, also is a long-standing distributor of instruments and services for Agilent.

Why Purchase the Report?

  • Visualize the composition of the transient protein expression market segmentation by product type, by application and by end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in transient protein expression market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of transient protein expression market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global transient protein expression market report would provide an access to an approx. 61 market data table, 55 figures and 200 pages. 

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version